Nephros (NEPH) Income from Discontinued Operations (2021 - 2022)
Nephros (NEPH) posted Income from Discontinued Operations of -$129000.0 for Q4 2022, up 93.22% on a QoQ basis from -$1.9 million in Q3 2022, and up 59.31% year-over-year from -$80976.2 in Q4 2021.
Powered by 
Analysis
Nephros (NEPH) Income from Discontinued Operations (2021 - 2022) Analysis & Trends
Nephros has reported Income from Discontinued Operations for 2 years, with the latest figure at -$129000.0 in Q4 2022.
- On a quarterly basis, Income from Discontinued Operations rose 59.31% year-over-year to -$129000.0 in Q4 2022; TTM through Dec 2022 was -$2.8 million, a N/A change from a year earlier, with the FY2022 full-year figure at -$2.8 million, down 161.22% from the prior year.
- Income from Discontinued Operations was -$129000.0 for Q4 2022 at Nephros, up from -$1.9 million in the prior quarter.
- The five-year high for Income from Discontinued Operations was -$129000.0 in Q4 2022, with the low at -$1.9 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 178.01 Bn | 172.41 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 131.29 Bn | 126.08 Bn | 1.96 Bn | - |
| 3 | Medtronic | 116.38 Bn | 107.56 Bn | 6.34 Bn | - |
| 4 | Stryker | 106.01 Bn | 102.53 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.40 Bn | 62.86 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 48.89 Bn | 44.64 Bn | 1.35 Bn | - |
| 7 | Alcon | 32.59 Bn | 31.13 Bn | 1.68 Bn | - |
| 8 | Dexcom | 31.84 Bn | 29.89 Bn | 830.00 Mn | - |
| 9 | Steris | 20.61 Bn | 20.13 Bn | 684.20 Mn | - |
| 10 | Nephros | 48.31 Mn | 43.62 Mn | 4.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -129,000.00 |
| Sep 30, 2022 | -1.90 Mn |
| Jun 30, 2022 | -390,000.00 |
| Mar 31, 2022 | -406,000.00 |
| Dec 31, 2021 | -317,000.00 |
| Sep 30, 2021 | -360,000.00 |